منابع مشابه
Biosimilar medicines and cost-effectiveness
Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to introduce and describe specific issues related to the economic evaluation of biosimilars by focusing on the relative costs, relative effectiveness, and cost-effectiveness of biosimilars. Economic evaluation assesses the cost-effectiveness of a medicine by comparing the cos...
متن کاملECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
Biologics have become key agents for the management of Crohn's disease and ulcerative colitis. Biosimilars are biological medicines similar to previously authorized biologics and are already available in some countries. This ECCO Position Statement defines the collective view of European specialist in inflammatory bowel disease (IBD) concerning biosimilars. Biosimilars are not comparable to gen...
متن کاملBiosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines
For many years European governments have sought to ensure a high degree of competition in off-patent pharmaceutical markets in order to generate price competition and consequently benefits such as improved patient access or savings for payers after patent expiry. The pharmaceutical industry believes that access to valuable new treatments and post-exclusivity competition are essential for the su...
متن کاملThe use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
A biosimilar is a biologic product that is similar to a reference biopharmaceutical product, the manufacturing process of which hinders the ability to identically replicate the structure of the original product, and therefore, it cannot be described as an absolute equivalent of the original medication. The currently available technology does not allow for an accurate copy of complex molecules, ...
متن کاملThe use of biosimilar drugs in psoriasis: a position paper.
-The development of biologic therapy has substantially improved the treatment of psoriasis and psoriatic arthritis. At the same time, the elevated cost of biologics has prompted debate on the economic sustainability of the public health system. -As patents expire for biologics, business interests and the high capacity of today’s biotechnology industry have encouraged laboratories to develop new...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2017
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2017-001372